Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

The Lancet Gastroenterology and Hepatology

Volumn 3, Issue 2, 2018, Pages 125-133

  Marshall, Alison D ^a   Cunningham, Evan B ^a   Nielsen, Stine ^b   Aghemo, Alessio ^c   Alho, Hannu ^d   Backmund, Markus ^e   Bruggmann, Philip ^f   Dalgard, Olav ^g   Seguin Devaux, Carole ^h   Flisiak, Robert ⁱ   Foster, Graham R ^j   Gheorghe, Liana ^k   Goldberg, David ^l   Goulis, Ioannis ^m   Hickman, Matthew ⁿ   Hoffmann, Patrick ^o   Jancorienė, Ligita ^p   Jarcuska, Peter ^q   Kåberg, Martin ^r   Kostrikis, Leondios G ^s   Makara, Mihály ^t   Maimets, Matti ^u   Marinho, Rui Tato ^v   Matičič, Mojca ^w   Norris, Suzanne ^x   Ólafsson, Sigurður ^y   Øvrehus, Anne ^z   Pawlotsky, Jean Michel ^aa   Pocock, James ^ab   Robaeys, Geert ^ac,ad,ae   Roncero, Carlos ^af   Simonova, Marieta ^ag   Sperl, Jan ^ah   Tait, Michele ^x   Tolmane, Ieva ^ai,aj   Tomaselli, Stefan ^ak   van der Valk, Marc ^al   Vince, Adriana ^am   Dore, Gregory J ^a   Lazarus, Jeffrey V ^an,ao   Grebely, Jason ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b INHSU   (Spain)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF MUNICH   (Germany)

^f Arud Centres for Addiction Medicine   (Switzerland)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^h LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

ⁱ MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k FUNDENI CLINICAL INSTITUTE   (Romania)

^l HEALTH PROTECTION SCOTLAND   (United Kingdom)

^m ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁿ UNIVERSITY OF BRISTOL   (United Kingdom)

^o Ministry of Health   (Luxembourg)

^p VILNIUS UNIVERSITY   (Lithuania)

^q L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s UNIVERSITY OF CYPRUS   (Cyprus)

^t Szent Laszlo Hospital   (Hungary)

^u UNIVERSITY OF TARTU   (Estonia)

^v UNIVERSITY OF LISBON   (Portugal)

^w UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^x DR STEEVENS HOSPITAL   (Ireland)

^y LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^z ODENSE UNIVERSITY HOSPITAL   (Denmark)

^aa HENRI MONDOR HOSPITAL   (France)

^ab MATER DEI HOSPITAL   (Malta)

^ac DEPARTMENT OF CARDIOLOGY   (Belgium)

^ad HASSELT UNIVERSITY   (Belgium)

^ae UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^af HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^ag MILITARY MEDICAL ACADEMY   (Bulgaria)

^ah INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^ai RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^aj UNIVERSITY OF LATVIA   (Latvia)

^ak Office for Public Health   (Liechtenstein)

^al ACADEMIC MEDICAL CENTER   (Netherlands)

^am Croatia   (Croatia)

^an CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^ao UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR; ELBASVIR; GRAZOPREVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR;

ALCOHOL CONSUMPTION; DRUG USE; FIBROSIS; GENERAL PRACTITIONER; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MIXED INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; REIMBURSEMENT; CHRONIC HEPATITIS C; COMPLICATION; DRUG COST; ECONOMICS; EUROPEAN UNION; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SWITZERLAND;

ANTIVIRAL AGENTS; COINFECTION; DRUG COSTS; EUROPEAN UNION; HEALTH POLICY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; SWITZERLAND;

EID: 85041530359     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30284-4     Document Type: Note

References (61)

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
2. WHO. Global hepatitis report, 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1, April, 2017 (accessed June 23, 2017).
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
4. Dore, GJ, Feld, JJ, Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis 60 (2015), 1829–1836.
5. Wedemeyer, H, Dore, GJ, Ward, JW, Estimates on HCV disease burden worldwide—filling the gaps. J Viral Hepat 22:suppl 1 (2015), 1–5.
6. Gane, E, Kershenobich, D, Seguin-Devaux, C, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden—volume 2. J Viral Hepat 22:suppl 1 (2015), 46–73.
7. Nahon, P, Bourcier, V, Layese, R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152 (2017), 142–156.
8. Barua, S, Greenwald, R, Grebely, J, Dore, GJ, Swan, T, Taylor, LE, Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
9. Marshall, AD, Saeed, S, Barrett, L, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 4 (2016), E605–E614.
10. Ooka, K, Connolly, JJ, Lim, JK, Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C. Am J Gastroenterol 112 (2017), 828–832.
11. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
12. European Association for the study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
13. WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/, 2016 (accessed Jan 12, 2017).
14. Razavi, H, Robbins, S, Zeuzem, S, et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 325–336.
15. Hajarizadeh, B, Grebely, J, Dore, GJ, Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10 (2013), 553–562.
16. Hatzakis, A, Chulanov, V, Gadano, AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm—volume 2. J Viral Hepat 22:suppl 1 (2015), 26–45.
17. Saraswat, V, Norris, S, de Knegt, RJ, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 2. J Viral Hepat 22:suppl 1 (2015), 6–25.
18. WHO. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/, June, 2016 (accessed May 21, 2017).
19. Sykehusinnkjøp, HF, HCV guidelines for the Norwegian Health Authorities. http://sykehusinnkjop.no/wp-content/uploads/2017/02/LIS-HCV-anbefalinger-2017-leverand%C3%B8rer.pdf, Feb 8, 2017 (accessed May 10, 2017).
20. Norwegian Medical Association. Clinical recommendations for hepatitis C treatment in Norway. http://www.hepatittfag.no/om#bakgrunn, March, 2017 (accessed May 5, 2017; in Norwegian).
21. Schweizerische Eidgenossenschaft. Index of the specialty list directories. 2017. Online Drug Formulary. http://www.spezialitaetenliste.ch/ (accessed Feb 23, 2017).
22. Chandrasekhar, A, Swiss hepatitis C sufferers to get full access to expensive drug. https://www.swissinfo.ch/eng/zepatier-_swiss-hepatitis-c-sufferers-to-get-full-access-to-expensive-drug/43288924, June 26, 2017 (accessed June 27, 2017).
23. Erstattungskodex (EKO). In focus tips. New in EKO. May, June, and July 2017. http://www.bgkk.at/cdscontent/load?contentid=10008.642874&version=1499412330, 2017 (accessed Aug 1, 2017).
24. Swiss Confederation. Drugs against hepatitis C: strong price reduction and extended remuneration. www.bag.admin.ch/bag/de/home/aktuell/news/news-26-06-2017.html, 2017 (accessed June 27, 2017).
25. Belgian Association for the Study of the Liver. Belgian HCV therapy guidance update. http://www.basl.be/sites/default/files/Belgian%20HCV%20therapy%20guidance%20update%20january%202017_final_25012017.pdf, January 2017 (accessed May 19, 2017).
26. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia. Issue 6. https://kirby.unsw.edu.au/sites/default/files/kirby/report/Monitoring-hep-C-treatment-uptake-in-Australia_Iss6-FEB17.pdf, February, 2017 (accessed March 17, 2017).
27. Arora, S, Thornton, K, Murata, G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 364 (2011), 2199–2207.
28. Kattakuzhy, SM, Gross, C, Teferi, G, et al. High efficacy of HCV treatment by primary care providers: the ASCEND study. Conference on retroviruses and opportunistic infections. Boston, MA, USA. http://hepcasia.com/wp-content/uploads/2015/03/HCV-treatment-via-primary-care-providers.pdf, Feb 22–25, 2016 (accessed July 5, 2017).
29. Grebely, J, Dore, GJ, What is killing people with hepatitis C virus infection?. Semin Liver Dis 31 (2011), 331–339.
30. van der Meer, AJ, Wedemeyer, H, Feld, JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
31. Martin, NK, Vickerman, P, Grebely, J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
32. Asher, AK, Portillo, CJ, Cooper, BA, Dawson-Rose, C, Vlahov, D, Page, KA, Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse 51 (2016), 1218–1223.
33. Grebely, J, Oser, M, Taylor, LE, Dore, GJ, Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 207:suppl 1 (2013), S19–S25.
34. Norton, BL, Fleming, J, Steinman, M, et al. High HCV cure rates for drug users treated with direct acting antiviral theray at an urban primary care clinic. Int J Drug Policy 47 (2017), 196–201.
35. Conway, B, Raycraft, T, Bhutani, Y, et al. Efficacy of all-oral HCV therapy in people who inject drugs. Hepatology, 64, 2016, 990A (abstr).
36. Sulkowski, M, Ward, K, Falade-Nwulia, O, et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study. J Hepatol, 66, 2017, S719.
37. Mason, K, Dodd, Z, Guyton, M, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence amongst people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 47 (2017), 202–208.
38. Morris, L, Smirnov, A, Kvassay, A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors' Health Network. Int J Drug Policy, 2017 published online June 27. DOI:10.1016/j.drugpo.2017.05.056.
39. Read, P, Lothian, R, Chronister, K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy, 2017 published online June 4. DOI:10.1016/j.drugpo.2017.05.032.
40. Puoti, M, Cooper, C, Sulkowski, MS, et al. ABT-450/r/Ombitasvir plus dasabuvir with or without ribavirin in HCV genotype 1-infected patients receiving stable opioid substitution treatment: pooled analysis of efficacy and safety in phase 2 and phase 3 trials. Hepatology 60 (2014), 1135a–1136a.
41. Feld, JJ, Kowdley, KV, Coakley, E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370 (2014), 1594–1603.
42. Zeuzem, S, Ghalib, R, Reddy, KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
43. Grebely, J, Dore, GJ, Zeuzem, S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis 63 (2016), 1479–1481.
44. Grebely, J, Mauss, S, Brown, A, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis 63 (2016), 1405–1411.
45. Grebely, J, Puoti, M, Wedemeyer, H, et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. J Hepatol, 66, 2017, S514.
46. Grebely, J, Jacobson, IM, Kayali, Z, et al. Sof/vel/vox for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. J Hepatol, 66, 2017, S513.
47. Lalezari, J, Sullivan, JG, Varunok, P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 63 (2015), 364–369.
48. Dore, GJ, Altice, F, Litwin, AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 165 (2016), 625–634.
49. Bouscaillou, J, Kikvidze, T, Butsashvili, M, et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia. J Hepatol, 66, 2017, S409.
50. Boglione, L, Mornese Pinna, S, De Nicolo, A, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepat, 2017 published online March 26. DOI:10.1111/jvh.12711.
51. Grebely, J, Dalgard, O, Conway, B, et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study. J Hepatol, 66, 2017, S513.
52. Dore, GJ, Altice, F, Litwin, AH, et al. Elbasvir/grazoprevir to treat HCV infection in persons receiving opioid agonist therapy: a randomized controlled trial (C-EDGE CO-STAR). Ann Intern Med 165 (2016), 625–634.
53. Aspinall, EJ, Corson, S, Doyle, JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57:suppl 2 (2013), S80–S89.
54. Grebely, J, Haire, B, Taylor, LE, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments—Is this fair, given the available data?. J Hepatol 63 (2015), 779–782.
55. Liakina, V, Hamid, S, Tanaka, J, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 3. J Viral Hepat 22:suppl 4 (2015), 4–20.
56. Bruggmann, P, Berg, T, Ovrehus, AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 21:suppl 1 (2014), 5–33.
57. WHO. Manual for the development and assessment of national viral hepatitis plans. www.who.int/hepatitis/publications/manual-hep-plan/en/, September, 2015 (accessed May 19, 2017).
58. European Liver Patients Association. The 2016 Hep-Core report. Monitoring the implementation of hepatitis B and C policy recommendations in Europe. http://www.elpa.eu/sites/default/files/project-documents/Hep-CORE_full_report_21Mar2017_errata_Final.pdf, March, 2017 (accessed May 30, 2017).
59. WHO. Regional committee for Europe 66th session. Action plan for the health sector response to viral hepatitis in the WHO European Region. http://www.euro.who.int/en/about-us/governance/regional-committee-for-europe/66th-session/documentation/working-documents/eurrc6610-action-plan-for-the-health-sector-response-to-viral-hepatitis-in-the-who-european-region, September, 2016 (accessed June 23, 2017).
60. Muhlberger, N, Schwarzer, R, Lettmeier, B, Sroczynski, G, Zeuzem, S, Siebert, U, HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health, 9, 2009, 34.
61. Scott, N, McBryde, ES, Thompson, A, Doyle, JS, Hellard, ME, Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut 66 (2016), 1507–1515.